Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Nexstar And Hawaiian Telcom Reach Multi-Year Distribution Agreement

Agreement Covers Nexstar's Local TV Stations KHON-TV (FOX), KHON2 (CW), and KHII-TV (MyNet), Cable News Network NewsNation, and Digital Subchannel Rewind TV Nexstar Media Group, Inc. (NASDAQ:NXST) and Hawaiian
byHappy Mohamed
July 21, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Agreement Covers Nexstar’s Local TV Stations KHON-TV (FOX), KHON2 (CW), and KHII-TV (MyNet), Cable News Network NewsNation, and Digital Subchannel Rewind TV

Nexstar Media Group, Inc. (NASDAQ:NXST) and Hawaiian Telcom today announced that they have reached a comprehensive multi-year distribution agreement covering Nexstar’s three local television stations serving Hawaii, national cable news network, NewsNation, and the company’s digital network, Rewind TV.

The agreement means that thousands of Hawaiian Telecom subscribers will once again be able to enjoy Nexstar’s high-quality national and local content without interruption, including their favorite network entertainment programming, Women’s World Cup soccer matches, and the in-depth local news, weather and sports coverage provided by KHON-TV, KHON2 and KHII-TV. Financial terms of the agreement we not disclosed.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Bill Holdings Q2 Earnings: Revenue And EPS Beat, Hikes Outlook And More

By Erica Kollmann
February 8, 6:13 PM
Bill Holdings reported quarterly earnings of 63 cents per share, beating the analyst consensus estimate of 40 cents by 57.5% and representing a 50% increase over earnings of 42 cents per share year-over-year. The company reported quarterly sales of $318.5 million which beat the analyst consensus estimate of $298.14 million by 6.83% and is a 22.5% increase over sales of $260.01 million from the same period last year.

BILL

Read More

AstraZeneca And Daiichi Sankyo’s Datopotamab Deruxtecan Extended Progression-Free Survival Vs. Chemotherapy In Patients With HR-Positive, HER2-Low Or Negative Breast Cancer In TROPION-Breast01 Phase III Trial

By Benzinga Newsdesk
October 23, 10:31 AM
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy settingPositive

AZN